Sign in

BDRX on Nasdaq

Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc is a British pharmaceutical preparations company based in Caspian Way.2 Its shares trade on Nasdaq under the symbol BDRX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerBDRX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersCaspian Way, United Kingdom2
  • Incorporated inUnited Kingdom3
  • Business address1 Caspian Point, Caspian Way, Cardiff, Cf10 4Dq3
  • Filer categoryNon-accelerated filer3
  • Legal formOther2
  • LEI549300GKR2G40H3QFY572
  • StatusActive2
  • LEI statusIssued and current2
  • Registered address1 Caspian Point, CF10 4DQ Caspian Way, United Kingdom2
  • Registered withCompanies House, 092163682

See how the biggest companies compare on our leaderboards

Tolimidone, which was in-licensed in December 2023, is undergoing a Phase 2a IIT at the University of Alberta Diabetes Institute for T1D.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenue381.0K GBP
Other income152.0K GBP31.0K GBP14.0K GBP
Research and development costs-4.0M GBP-5.4M GBP-4.1M GBP
Administrative costs-4.8M GBP-3.8M GBP-4.3M GBP
Loss from operations-8.6M GBP-9.2M GBP-8.0M GBP
Finance income2.4M GBP3.4M GBP570.0K GBP
Finance expense-229.0K GBP-165.0K GBP-41.0K GBP
Loss before tax-6.5M GBP-6.0M GBP-7.5M GBP
Taxation105.0K GBP250.0K GBP406.0K GBP
Loss for the year attributable to the owners of the parent-6.4M GBP-5.7M GBP-7.1M GBP
Exchange gains arising on translation of foreign operations3.0K GBP
Total other comprehensive income net of tax3.0K GBP
Total comprehensive loss attributable to the owners of the parent-6.4M GBP-5.7M GBP-7.1M GBP
Basic loss perordinary share-0.00 GBP-0.00 GBP-0.02 GBP
Diluted loss perordinary share-0.00 GBP-0.00 GBP-0.02 GBP

Compare Biodexa Pharmaceuticals Plc with another company

Corporate structure

Biodexa Pharmaceuticals Plc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Biodexa Pharmaceuticals Plc

  • Biodexa Pharmaceuticals Plc Caspian Way, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Biodexa Pharmaceuticals Plc, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Fiona Mary Powell2026–now
Board members and other officers (5)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorStephen Stamp named Feb 17, 2023 to Aug 1, 202411
  • Executive OfficerDmitry Zamoryakhin named Feb 17, 2023 to Jan 4, 202412
  • DirectorSijmen de Vries named Feb 17, 2023 to Aug 1, 202411

Former names

  • Midatech Pharma PlcJun 4, 2015 to Mar 27, 20233

Timeline

  1. Sep 12, 2014Founded Biodexa Pharmaceuticals Plc is founded2

Filings

512 filings to the SEC since October 2021: 6 annual reports, 6 insider forms, 23 large holders, 4 private raises, 473 other. The latest 20:

  1. Oct 14, 2026424B3 333-299106 EDGAR
  2. Oct 14, 2026424B3 333-297473 EDGAR
  3. Oct 14, 2026424B3 PROSPECTUS SUPPLEMENT NO. 5 EDGAR
  4. Oct 14, 2026424B3 333-284350 PROSPECTUS SUPPLEMENT NO. 5 EDGAR
  5. Oct 14, 2026424B3 333-281489 EDGAR
  6. Oct 14, 2026424B3 333-279994 EDGAR
  7. Oct 14, 2026424B3 PROSPECTUS SUPPLEMENT NO. 5 EDGAR
  8. Oct 14, 2026424B3 PROSPECTUS SUPPLEMENT NO. 5 EDGAR
  9. Oct 14, 20266-K EDGAR
  10. Oct 8, 20266-K EDGAR
  11. Oct 6, 2026424B3 EDGAR
  12. Sep 30, 2026EFFECT EDGAR
  13. Sep 24, 2026F-1 WARRANT INDUCEMENT EDGAR
  14. Sep 15, 2026424B3 EDGAR
  15. Sep 15, 2026424B3 EDGAR
  16. Sep 15, 2026424B3 EDGAR
  17. Sep 15, 2026424B3 EDGAR
  18. Sep 15, 2026424B3 EDGAR
  19. Sep 15, 2026424B3 EDGAR
  20. Sep 15, 2026424B3 EDGAR

The 512 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$21.1M 2023–2024
Money received by yearMoney received by year, 2023–2024: $21.1M in all. Private raises (Form D) $21.1M.$0$5M$10M$15M$20M2023 · Private raises (Form D): $16.1M20232024 · Private raises (Form D): $5.0M2024
Figures by year
YearPrivate raises (Form D)Total
2024$5.0M$5.0M
2023$16.1M$16.1M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jul 19, 2024Raised $5 million in a private offering of securities11 Form D: 7 investors so far Form D
  2. Dec 21, 2023Raised $6.8 million in a private offering of equity12 Form D: 1 investor so far Form D
  3. May 23, 2023Raised $3.3 million in a private offering of equity23 Form D: 15 investors so far Form D
  4. Feb 9, 2023Raised $6 million in a private offering of equity24 Form D: 6 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Armistice Capital, LLC14,809$43.1K0.0%New
GAMMA Investing LLC1,203$3.5K0.0%New
Allied Private Wealth LLC489$1.3K0.0%New
SBI Securities Co., Ltd.29$840.0%−122
UBS Group AG25$730.0%New
Hilton Head Capital Partners, LLC6$170.0%New
Caitong International Asset Management Co., Ltd5$150.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Biodexa Pharmaceuticals Plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBiodexa Pharmaceuticals Plc1
  • CIK0001643918
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inD54
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom1
  • Phone44 (0)1235 8883001
  • Shares outstanding225,817,808,922 shares as of Dec 31, 20254
  • AuditorPKF Littlejohn LLP, London, England PCAOB ID 2814; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJun 4, 20151
  • Filings731 in all: 6-K (267), 424B3 (243), EFFECT (35), CORRESP (21), POS AM (20), UPLOAD (17), SC 13G (12), SC 13G/A (12)1
    All 38 form types

    20-F (11), F-1 (11), 424B5 (7), F-1/A (7), 3 (6), 425 (6), D (6), 6-K/A (5), CT ORDER (5), F-4/A (4), SCHEDULE 13G (4), SD (4), 20-F/A (3), F-3 (3), F-6 POS (3), SCHEDULE 13G/A (3), 424B4 (2), S-8 (2), 8-A12B (1), 8-A12B/A (1), CERTNAS (1), DRS (1), DRSLTR (1), F-3/A (1), F-4 (1), F-6 (1), F-6/A (1), FWP (1), S-8 POS (1), SC 13D (1)

  • Latest filingsAnnual report (20-F) Mar 27, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing 100,000 ordinary sharesBDRXNASDAQ

From the cover page of the 20-F filed Mar 27, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24